Evotec (NASDAQ:EVO) Shares Gap Up to $5.02

Evotec SE (NASDAQ:EVO)’s stock price gapped up before the market opened on Monday . The stock had previously closed at $5.02, but opened at $5.22. Evotec shares last traded at $5.25, with a volume of 79,727 shares traded.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on EVO shares. Royal Bank of Canada raised shares of Evotec from a “sector perform” rating to an “outperform” rating in a research note on Thursday, January 18th. Deutsche Bank Aktiengesellschaft raised shares of Evotec from a “hold” rating to a “buy” rating in a research report on Friday, April 12th. Finally, HC Wainwright dropped their price objective on shares of Evotec from $14.00 to $11.00 and set a “buy” rating for the company in a research report on Thursday.

Evotec Trading Up 3.4 %

The stock’s 50 day simple moving average is $7.24 and its 200 day simple moving average is $8.61.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Quadrant Capital Group LLC bought a new stake in Evotec in the 4th quarter valued at about $25,000. Optiver Holding B.V. lifted its position in Evotec by 643.1% in the 4th quarter. Optiver Holding B.V. now owns 80,810 shares of the company’s stock valued at $945,000 after purchasing an additional 69,936 shares during the last quarter. Finally, Mubadala Investment Co PJSC bought a new stake in Evotec in the 4th quarter valued at about $53,931,000. 5.81% of the stock is currently owned by institutional investors.

About Evotec

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health.